Media headlines about Intec Pharma (NASDAQ:NTEC) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intec Pharma earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.9755121171951 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of Intec Pharma (NASDAQ NTEC) traded up 3.15% during trading on Friday, reaching $6.55. 11,412 shares of the company were exchanged. Intec Pharma has a 1-year low of $4.20 and a 1-year high of $6.80. The stock’s 50 day moving average is $5.61 and its 200 day moving average is $5.31. The company’s market capitalization is $89.98 million.

A number of brokerages recently commented on NTEC. Zacks Investment Research cut shares of Intec Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, August 15th. Maxim Group set a $9.00 target price on shares of Intec Pharma and gave the stock a “buy” rating in a research report on Wednesday, May 24th. ValuEngine cut shares of Intec Pharma from a “hold” rating to a “sell” rating in a research report on Friday, June 9th. Finally, Roth Capital set a $10.00 target price on shares of Intec Pharma and gave the stock a “buy” rating in a research report on Thursday, August 10th.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/intec-pharma-ntec-receives-daily-news-sentiment-score-of-0-06/1524936.html.

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Insider Buying and Selling by Quarter for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.